Protagonist Therapeutics Inc (DE:PGF)

NASDAQ:PGF

PGF

Protagonist Therapeutics

RESEARCH TOOLSreports

Protagonist Therapeutics (PGF) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PGF Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Protagonist

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PGF Stock 12 Month Forecast

Average Price Target

€102.67

▲(36.89% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is €102.67 with a high forecast of €119.42 and a low forecast of €87.17. The average price target represents a 36.89% change from the last price of €75.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"41":"€41","120":"€120","60.75":"€60.8","80.5":"€80.5","100.25":"€100.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119.42328086,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€119.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.66721631111112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€102.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.170278,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€87.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[41,60.75,80.5,100.25,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,78.41717545076924,81.83435090153846,85.25152635230769,88.66870180307693,92.08587725384615,95.50305270461538,98.92022815538462,102.33740360615386,105.75457905692308,109.17175450769231,112.58892995846153,116.00610540923077,{"y":119.42328086,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,77.12824740854701,79.25649481709402,81.38474222564102,83.51298963418803,85.64123704273504,87.76948445128205,89.89773185982907,92.02597926837608,94.15422667692309,96.28247408547008,98.4107214940171,100.53896890256411,{"y":102.66721631111112,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,75.93617523076924,76.87235046153846,77.8085256923077,78.74470092307692,79.68087615384616,80.61705138461538,81.55322661538462,82.48940184615384,83.42557707692308,84.3617523076923,85.29792753846154,86.23410276923076,{"y":87.170278,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€119.42

Average Price Target€102.67

Lowest Price Target€87.17

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

06/22/26

Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP), Protagonist Therapeutics (NASDAQ: PTGX) and Resmed (NYSE: RMD)

Richard Law CFA

Goldman Sachs

€84.56→€95.89

Hold

27.85%

Upside

Reiterated

06/10/26

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX), Gilead Sciences (NASDAQ: GILD) and Edwards Lifesciences (NYSE: EW)

Brian Cheng

J.P. Morgan

€92.4→€98.5

Buy

31.34%

Upside

Reiterated

05/13/26

Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL), Protagonist Therapeutics (NASDAQ: PTGX) and Nuvalent (NASDAQ: NUVL)

Douglas Tsao

H.C. Wainwright

€101.99

Buy

35.99%

Upside

Reiterated

05/11/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Protagonist Therapeutics (PTGX)

Geoff Meacham

Citi

€108.96→€113.32

Buy

51.10%

Upside

Reiterated

05/10/26

Protagonist Therapeutics price target raised to $130 from $125 at CitiProtagonist Therapeutics price target raised to $130 from $125 at Citi

Etzer Darout

Barclays

€103.73

Buy

38.31%

Upside

Reiterated

05/06/26

Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Jonathan Wolleben

Citizens JMP

€104.6→€119.42

Buy

59.23%

Upside

Reiterated

05/06/26

Protagonist Therapeutics price target raised to $137 from $120 at CitizensProtagonist Therapeutics price target raised to $137 from $120 at Citizens

Yun Zhong

Wedbush

€97.63→€102.86

Buy

37.15%

Upside

Assigned

05/06/26

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM), Protagonist Therapeutics (NASDAQ: PTGX) and DENTSPLY SIRONA (NASDAQ: XRAY)

Tara Bancroft

TD Cowen

€87.17

Buy

16.23%

Upside

Reiterated

05/05/26

Analysts' Top Healthcare Picks: Biodesix (BDSX), Protagonist Therapeutics (PTGX)

Kaveri Pohlman

Clear Street

€90.66→€101.12

Buy

34.82%

Upside

Reiterated

04/06/26

Protagonist Therapeutics price target raised to $116 from $104 at Clear StreetProtagonist Therapeutics price target raised to $116 from $104 at Clear Street

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

€93.27→€95.89

Buy

27.85%

Upside

Reiterated

03/19/26

Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€82.81

Buy

10.42%

Upside

Reiterated

12/19/25

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Julian Harrison

BTIG

€71.48

Buy

-4.69%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)

Evan Seigerman

BMO Capital

€62.76→€97.63

Buy

30.17%

Upside

Reiterated

10/13/25

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€62.76

Buy

-16.32%

Downside

Initiated

09/17/25

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

06/22/26

Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP), Protagonist Therapeutics (NASDAQ: PTGX) and Resmed (NYSE: RMD)

Richard Law CFA

Goldman Sachs

€84.56→€95.89

Hold

27.85%

Upside

Reiterated

06/10/26

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX), Gilead Sciences (NASDAQ: GILD) and Edwards Lifesciences (NYSE: EW)

Brian Cheng

J.P. Morgan

€92.4→€98.5

Buy

31.34%

Upside

Reiterated

05/13/26

Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL), Protagonist Therapeutics (NASDAQ: PTGX) and Nuvalent (NASDAQ: NUVL)

Douglas Tsao

H.C. Wainwright

€101.99

Buy

35.99%

Upside

Reiterated

05/11/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Protagonist Therapeutics (PTGX)

Geoff Meacham

Citi

€108.96→€113.32

Buy

51.10%

Upside

Reiterated

05/10/26

Protagonist Therapeutics price target raised to $130 from $125 at CitiProtagonist Therapeutics price target raised to $130 from $125 at Citi

Etzer Darout

Barclays

€103.73

Buy

38.31%

Upside

Reiterated

05/06/26

Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Jonathan Wolleben

Citizens JMP

€104.6→€119.42

Buy

59.23%

Upside

Reiterated

05/06/26

Protagonist Therapeutics price target raised to $137 from $120 at CitizensProtagonist Therapeutics price target raised to $137 from $120 at Citizens

Yun Zhong

Wedbush

€97.63→€102.86

Buy

37.15%

Upside

Assigned

05/06/26

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM), Protagonist Therapeutics (NASDAQ: PTGX) and DENTSPLY SIRONA (NASDAQ: XRAY)

Tara Bancroft

TD Cowen

€87.17

Buy

16.23%

Upside

Reiterated

05/05/26

Analysts' Top Healthcare Picks: Biodesix (BDSX), Protagonist Therapeutics (PTGX)

Kaveri Pohlman

Clear Street

€90.66→€101.12

Buy

34.82%

Upside

Reiterated

04/06/26

Protagonist Therapeutics price target raised to $116 from $104 at Clear StreetProtagonist Therapeutics price target raised to $116 from $104 at Clear Street

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

€93.27→€95.89

Buy

27.85%

Upside

Reiterated

03/19/26

Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€82.81

Buy

10.42%

Upside

Reiterated

12/19/25

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Julian Harrison

BTIG

€71.48

Buy

-4.69%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)

Evan Seigerman

BMO Capital

€62.76→€97.63

Buy

30.17%

Upside

Reiterated

10/13/25

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€62.76

Buy

-16.32%

Downside

Initiated

09/17/25

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

3 Months

Brian ChengJ.P. Morgan

Success Rate

15/17 ratings generated profit

Average Return

+16.65%

Copying Brian Cheng's trades and holding each position for 3 Months would result in 88.24% of your transactions generating a profit, with an average return of +16.65% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

26/26 ratings generated profit

Average Return

+80.83%

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +80.83% per trade.

2 Years

Jonathan WollebenCitizens JMP

Success Rate

26/26 ratings generated profit

Average Return

+199.31%

Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +199.31% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PGF Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PGF has received 14 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PGF average Analyst price target in the past 3 months is 102.67.

Each month's total comprises the sum of three months' worth of ratings.

PGF Financial Forecast

PGF Earnings Forecast

Next quarter’s earnings estimate for PGF is €1.87 with a range of €1.18 to €2.46. The previous quarter’s EPS was €0.04. PGF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PGF has Performed in-line its overall industry.

PGF Sales Forecast

Next quarter’s sales forecast for PGF is €167.39M with a range of €17.61M to €216.95M. The previous quarter’s sales results were €49.63M. PGF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PGF has Performed in-line its overall industry.

PGF Stock Forecast FAQ

What is DE:PGF’s average 12-month price target, according to analysts?

Based on analyst ratings, Protagonist Therapeutics Inc’s 12-month average price target is 102.67.

What is DE:PGF’s upside potential, based on the analysts’ average price target?

Protagonist Therapeutics Inc has 36.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Protagonist Therapeutics Inc a Buy, Sell or Hold?

Protagonist Therapeutics Inc has a consensus rating of Strong Buy, which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Protagonist Therapeutics Inc’s share price target?

The average share price target for Protagonist Therapeutics Inc is 102.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €119.42 ,and the lowest forecast is €87.17. The average share price target represents 36.89% Increase from the current price of €75.

What do analysts say about Protagonist Therapeutics Inc?

Protagonist Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Protagonist Therapeutics Inc?

To buy shares of DE:PGF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Protagonist Therapeutics (PGF) Stock Forecast & Price Target

PGF Analyst Ratings

PGF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protagonist Therapeutics

PGF Analyst Recommendation Trends

PGF Financial Forecast

PGF Earnings Forecast

PGF Sales Forecast

PGF Stock Forecast FAQ

Detailed List of Analyst Forecasts